Brandywine Recalls Theophylline Extended-Release Tablets Due to Stability Testing Interruption
Brandywine Pharmaceuticals is recalling 1,620 bottles of Theophylline Extended-Release Tablets, 100 mg, due to an interruption in stability testing.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as Class II due to an interruption in stability testing, which may cause temporary or medically reversible adverse health consequences. The source does not report any illnesses, injuries, or deaths.
Plain-English summary
Brandywine Pharmaceuticals, LLC is recalling 1,620 100-count bottles of Theophylline Extended-Release Tablets, 100 mg, Rx Only (NDC: 71321-500-10). The recall was initiated because of an interruption in the ongoing stability testing program conducted at a third-party laboratory.
The affected product is identified by Lot 405617 with an expiration date of 03/31/2028. The product was distributed nationwide within the U.S. The source text does not report any illnesses, injuries, or deaths associated with this recall.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or healthcare provider for guidance on replacement or disposal.
The recalled product
- Product
- Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
- Manufacturer
- Brandywine Pharmaceuticals, LLC
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 405617
- Expiry: 03/31/2028
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Brandywine Pharmaceuticals, LLC
See all →- ModerateBrandywine Recalls Theophylline Extended-Release Tablets Due to Stability Testing Interruption
FDA (Drugs) · 2026-11-04
Same hazard · quality control
See all →- HighBaxter Recalls CARDENE IV Nicardipine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateBrandywine Recalls Theophylline Extended-Release Tablets Due to Stability Testing Interruption
FDA (Drugs) · 2026-11-04
- ModerateTheophylline Extended-Release Tablets recalled for dissolution test failure
FDA (Drugs) · 2025-06-04
- ModerateTorrent Pharma Recalls Lamotrigine Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2018-09-26
- ModerateNostrum Recalls Theophylline Tablets Due to Incorrect Lot and Expiration Dates
FDA (Drugs) · 2020-04-01
- ModerateTheophylline extended-release tablets failed dissolution at long-term stability testing
FDA (Drugs) · 2025-08-20
- SevereTeva Recalls Paliperidone Extended-Release Tablets Due to Dissolution Failure
FDA (Drugs) · 2017-07-19